President Trump wants to lower drug prices in the U.S. by tying them to the prices paid in other developed countries. The pharmaceutical industry has long opposed the approach.

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of its drug Zepbound.

New research suggests that pharmaceutical pollution can change the behavior of salmon in the wild.

Myra Solano Garcia, who has Alzheimer's, says the drug Kisunla may be one reason she can still drive, cook, and sing.

A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the agency's website, as the Trump administration halts DEI initiatives.

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to schizophrenia treatment. The Food and Drug Administration approved it Thursday.

Medicare's new authority to negotiate lower prescription drug prices represents a signature accomplishment of the Biden-Harris administration. Here's what to know as the first set of talks wraps up.

Insurance companies are covering fewer drugs than they used to, and patients have to jump through more hoops to get many of them. When shopping for insurance, check for coverage of the drugs you need.

Most of the largest pharmaceutical companies report losing money in the United States, despite the majority of their sales coming from Americans. The result is lower U.S. taxes for the companies.

The Senate HELP committee questioned pharmaceutical CEOs about how much more Americans pay for the same drugs sold for less in Canada, Japan and Europe.

Spoiler: There are some decreases this year, too. Here's an overview of the changing prices and what to make of them.

Hospitals rely on scores of generic drugs given by injection. But these workhorses are often in short supply. Cheap prices have led to factory closures that leave the supply chain vulnerable.

Stories of chronic pain, drug-hopping, and insurance meddling are all too common among patients with rheumatoid arthritis. Precision medicine offers new hope.

To lower drug prices, the Biden administration is looking to assert its authority to license drug patents that rely on government-funded research to drugmakers that would offer cheaper medicines.

The National Institutes of Health has been reluctant to use its leverage as a biomedical research funder to influence drug pricing. Sen. Bernie Sanders is pressing NIH's new director to take action.